By Serena Gordon
TUESDAY, Oct. 24, 2017 (HealthDay News) — Cholesterol-lowering medications known as statins may lower your risk of heart disease, nevertheless also might boost the odds you’ll develop type 2 diabetes, brand-new research suggests.
“In a group of people at high risk of type 2 diabetes, statins do seem to improve the risk of developing diabetes by about 30 percent,” said the study’s lead author, Dr. Jill Crandall. She’s a professor of medicine as well as director of the diabetes clinical trials unit at Albert Einstein College of Medicine in brand-new York City.
nevertheless, she added, in which doesn’t mean anyone should give up on statins.
“The benefits of statins in terms of cardiovascular risk are so strong as well as so well established in which our recommendation isn’t in which people should stop taking statins, nevertheless people should be monitored for the development of diabetes while on a statin,” she explained.
At least one different diabetes expert agreed in which statins are still beneficial for those at risk of heart trouble.
Dr. Daniel Donovan Jr. will be professor of medicine as well as director of clinical research at the Icahn School of Medicine at Mount Sinai Diabetes, Obesity as well as Metabolism Institute in brand-new York City.
“We still need to give statins when LDL (bad) cholesterol isn’t under control. A statin intervention can lower the risk of a cardiovascular event by 40 percent, as well as in which’s possible the diabetes may have been destined to happen,” he said.
The brand-new study will be an analysis of data collected by another ongoing study. More than 3,0 adults were recruited by 27 diabetes centers across the United States for the study.
The research goal was to prevent the progression of type 2 diabetes in people which has a high risk of the disease, Crandall said. All of the study participants were overweight or obese. They also all showed signs in which they weren’t metabolizing sugar properly at the start of the study, nevertheless not poorly enough to be diagnosed with type 2 diabetes.
Study volunteers were randomly chosen to get treatment with lifestyle modifications in which could lead to modest weight loss, the drug metformin or a placebo pill.
At the end of the intervention, they were asked to participate inside 10-year follow-up program. They had their blood sugar levels measured twice a year, as well as their statin use was tracked, too.
At the start of the follow-up period, 4 percent of participants were taking statins. At the end, about one-third were.
Simvastatin (Zocor) as well as atorvastatin (Lipitor) were the most commonly used statins.
The study was an observational study, so in which couldn’t show a cause as well as effect relationship.
However, Crandall said the researchers measured levels of insulin secretion as well as insulin resistance. Insulin will be a hormone in which helps the body usher the sugar by foods into the body’s cells to be used as fuel.
Crandall said insulin secretion goes down when people take statins. Less insulin could lead to higher blood sugar levels. She said there was no indication in which statins affected insulin resistance.
Donovan added in which the study provides important information. “nevertheless I don’t think the message will be stop statins,” he said. “Most people are probably developing heart disease before diabetes, as well as in which’s important to treat the risk factors you can.”
Though they weren’t included in in which study, people who already have type 2 diabetes should be closely monitored for increases in blood sugar when they start taking a statin, Crandall said. “The evidence so far will be rather limited, nevertheless there have certainly been anecdotal reports of blood sugar being higher when someone starts statins,” she said.
She also suggested in which blood sugar levels likely aren’t as much of a concern for those without diabetes or risk factors for diabetes when starting a statin. Besides excess weight, those risks include older age, high blood pressure as well as a family history of diabetes.
Crandall added in which there are many people 50 as well as over with prediabetes who don’t know in which, so in which could be an issue for them.
Findings by the study were published online Oct. 23 in BMJ Open Diabetes Research & Care.
Copyright © 2017 HealthDay. All rights reserved.
SOURCES: Jill Crandall, M.D., professor, medicine, as well as director, diabetes clinical trials unit, Albert Einstein College of Medicine, brand-new York City; Daniel D. Donovan Jr., M.D., professor, medicine, as well as director, clinical research, Icahn School of Medicine, Mount Sinai Diabetes, Obesity as well as Metabolism Institute, brand-new York City; Oct. 23, 2017, BMJ Open Diabetes Research & Care
Subscribe to MedicineNet’s Diabetes Newsletter